Plus   Neg

Gilead & Gritstone Partner To Develop HIV-specific Therapeutic Vaccine - Quick Facts

Gilead Sciences, Inc. (GILD) and Gritstone Oncology, Inc. (GRTS) have entered into a collaboration, option and license agreement. The companies will develop an HIV-specific therapeutic vaccine using Gritstone's prime-boost vaccine platform, with antigens developed by Gilead.

Gilead will make a $60 million payment at closing, consisting of a $30 million upfront cash payment and a $30 million equity investment. Gilead will be responsible for conducting a phase 1 study for the HIV-specific therapeutic vaccine. Gritstone is
also eligible to receive up to an additional $725 million, as well as mid single-digit to low double-digit tiered royalties on net sales.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
South Korea's Hyundai Motor Co. announced its decision to suspend production at its Asan plant for two days starting on Monday due to a chip shortage amid the pandemic crisis, Reuters reported. The company is experiencing trouble in supply conditions for semiconductor parts for powertrain control units. The Asan factory manufactures 300,000 vehicles, including the Sonata and Grandeur sedans, each The U.S. Department of Health and Human Services is set to expand its Health Center COVID-19 Vaccine Program to include all HRSA-funded health centers. This will increase the total number of health centers that have been invited to join the program to 1,470 nationwide from the earlier 950. McDonald's Corp. is planning to hire 25,000 workers in its restaurants across Texas in April, reports said. In a three-day event from April 13 to 15, the fast-food chain is expected to hire for crew and management positions. During these hiring days, participating McDonald's restaurants in the state will be accepting applications and interviewing job seekers.
Follow RTT